Dr. Venkat Sai. Gangapatnam, Dr. N. N. Anand


OBJECTIVE The objective This study was performed to determine the correlation between serum magnesium (Mg) and lipid profile in patients on maintenance hemodialysis (MHD).


MATERIAL &METHOD This hospital-based cross- sectional observational study was conducted at the Department of Medicine, sree balaji medical college , chennai . Fifty patients with end-stage kidney disease on MHD treatment (29 males and 21 females) were studied. The mean frequency being two to three sessions /week of hemodialysis and each session lasted for four hours. After obtaining informed written consent, the general information of each patient was recorded on a proforma. After overnight fasting, blood samples was drawn for complete hemogram, blood urea , serum creatinine, lipid profile and serum Mg.


RESULTS The serum magnesium was significantly correlated with diabetes in the study. ( P < 0.001) The mean BMI in CKD patients was 18.37 ± 1.82 kg/m2 In the present study most of the CKD patients was in Stage 5. i.e. 43 cases. Total serum Cholesterol levels (>200 mg/dl) was found higher than normal in 15 cases and the mean was 174.1 ± 44.62. The mean Serum Triglyceride levels was 144.54 ±

58.09 mg/ dl in CKD patients and it correlated significantly with serum magnesium. The mean HDL-C levels was 39.26 ± 6.40 mg/dl were lower in CKD patients found. in 30 patients among 50 cases. Serum magnesium in CKD patients significantly correlated with Age (P< 0.001), systolic blood pressure( p<0.001), serum Triglyceride levels (P=0.02), The mean age of the studied CKD patients was 45.46 ± 15.60 years (Range 18- 76).


CONCLUSION Magnesium may affect the metabolism of TG and HDL in liver and kidneys. The association of dyslipidemia with serum Mg levels is not clearly understood, and further large clinical studies are needed to understand this association better.



Full Text:



Pennell P, Leclercq B, Delahunty MI, Walton BA. The utility of non-HDL in managing dyslipidemia of stage 5 chronic kidney diseases. Clin Nephrol 2006;66(5):336.47.

Soubassi LP, Papadakis ED, Theodoropoutos IX, et al. Incidence and risk factors of coronary artery disease In patients on chronic hemodialysis. Int Artif Organs 2007;30(3):253-7.

Al Wake&15, Mitvralli AH, Al Mohaya 5, et al. Morbidity and mortality In ESRD patients on dialysis. Saudi J Kidney Dis I ramp' 2002;13 (4):473-7.

Manske CI.. icasiske Bt. Lipid abnormalities after renal transplantation. In: Keane WI, Stein 111, eds. Lipids and renal disease. Contemporary Issues in Nephrology, Churchill Livingstone, New York, 1991;3/-61.

Keane WP, oda H. Lipid abnormalities in end stage renal disease Nephrol Dial Transplant 1998;13(suppl 1):4S-9.

Kronenherg F, Kathrein H, Ko-nig P, et al. Apolipoprotein(a) • phenotypes predict the risk for carotid a inerostierosis in patients with end-stage renal disease. Arteriosder Thromb 1994; 14: 1405-11 .

Mountokalakis rD. Magnesium metabolism in chronic renal failure. MagnessRes 1990;3(2): 121-7.

Lindeman RD. Chronic renal failure and magnesium metabolism. Magnesium 1986;5(5-6): 293-300.

j. Elementol.,et al Evaluation of the correlations between magnesium concentration and selected serum lipid components in women and men of different age with chronic kidney failure2030,15(2): 321-329.

Nasir H, Baradaran A. Correlation of swum magnesium with dyslipidemia in maintenance hrunodialysis patients. Acta medics 2004; 47: 263-265.

Feng Lill, Xintian Zhanng et al. Corelataion of serum magnesium with cardiovascular risk factors in maintenance hernodialysis patients. A cross sectional study. Magnes res 2013 july-- sep ; 26(3); 100-8

Anson MR., tvlaheshwad Net al : Correlation or serum magnesium with dyslipidemia in patients on maintenance iie•odiaiys;s Saudi J kidney dis transplant. 2012 Jan;23(1):21-5.

Rebles Escola 1M, Aibarran 1, Espada R, Cruz A. Correlation of serum magnesium and serum lipid levels in hemodialysis patients. Dialysis & Transplantation 1998, volum 27,10 : 644.648 oct.


  • There are currently no refbacks.